statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

AMGEN HIGHLIGHTS NEW COPD, ASTHMA AND VASCULITIS RESEARCH AT ATS 2024 AMGEN HIGHLIGHTS NEW COPD, ASTHMA AND VASCULITIS RESEARCH AT ATS 2024 PR Newswire THOUSAND OAKS, Calif., May 1, 2024 Findings...

AMGEN HIGHLIGHTS NEW COPD, ASTHMA AND VASCULITIS RESEARCH AT ATS 2024

Sandoz resolves patent litigation with Amgen, paving the way for the launch of denosumab biosimilars Jubbonti and Wyost.
read more...

Sandoz Settles Patent Dispute With Amgen Related To Bone Disorder Drug Denosumab

AMGEN ANNOUNCES WEBCAST OF 2024 FIRST QUARTER FINANCIAL RESULTS AMGEN ANNOUNCES WEBCAST OF 2024 FIRST QUARTER FINANCIAL RESULTS PR Newswire THOUSAND OAKS, Calif., April 29, 2024 THOUSAND OAKS...

AMGEN ANNOUNCES WEBCAST OF 2024 FIRST QUARTER FINANCIAL RESULTS

Coming up: Fed rate decision, jobs report, and earnings from Apple, Amazon, AMD

 Justin Sullivan/Getty Images

 Key TakeawaysThe Federal Reserve is expected to leave interest rates unchanged...

What To Expect in the Markets This Week

For investors, each week in every month and every quarter has its own rhythms. Sometimes, it's almost quiet. This week will not be one of those quiet weeks. It has two hugely important economic...

Fed's Powell, jobs report and Apple will rock markets this week

AMGEN TO SUBMIT TEPROTUMUMAB MARKETING AUTHORIZATION APPLICATION TO THE EUROPEAN MEDICINES AGENCY AMGEN TO SUBMIT TEPROTUMUMAB MARKETING AUTHORIZATION APPLICATION TO THE EUROPEAN MEDICINES AGENCY PR...

AMGEN TO SUBMIT TEPROTUMUMAB MARKETING AUTHORIZATION APPLICATION TO THE EUROPEAN MEDICINES AGENCY

How Is The Market Feeling About Amgen?

Amgen's Tezspire shows promising COPD trial results and potential market expansion beyond asthma. Comparison with Dupixent reveals significant benefits for eosinophil counts 150 cells/ L and 300...

Amgen/AstraZeneca's Asthma Drug Tezspire Vs. Sanofi/Regeneron's Blockbuster Dupixent - Analyst Gives His Pick

AMGEN TO PRESENT TEZSPIRE PHASE 2A COPD DATA AT ATS 2024 AMGEN TO PRESENT TEZSPIRE PHASE 2A COPD DATA AT ATS 2024 PR Newswire THOUSAND OAKS, Calif., April 16, 2024 Planning Underway for Phase 3...

AMGEN TO PRESENT TEZSPIRE PHASE 2A COPD DATA AT ATS 2024

Final Trades: Shell, 2-YR T-Note and Amgen...

Final Trades: Shell, 2-YR T-Note and Amgen

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. It operates through Human Therapeutics segment. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Volume	2.32M
52-Wk High	$329.72
52-Wk Low	$211.71

AMGN AMGEN Inc.

About

Feed

News

Sentiment

Earnings

Fundamentals